Stockreport
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy. She also raised her price target estimate from $84 to $98, offering an upside of almost 75% from the prevailing level. RAJ CREATIONZS / shutterstock.com Ijem's upward revisions are based on the company's encouraging fundamentals and her optimism around BioMarin's potential acquisition of Amicus Therapeutics. She believes this deal could push the stock out of its previous trading range, which stayed between $60 and $70. On December 22, Joon Lee from Truist Securities also revised his price target forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) from $80 to $100. He also maintained his Buy rating on the stock, which offers nearly 78% potential upside. Lee also based his upgrades on prospects related to the acquisition of Amicus Therapeutics, expected to be finalized in the second quarter of 2026. The analyst sees this acquisition to be strategically a
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- Pharma companies left out of Trump's drug-pricing deals look for way in [Yahoo! Finance Canada][Yahoo! Finance Canada]
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance][Yahoo! Finance]
- Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance][Yahoo! Finance]
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility[PR Newswire]
- More
BMRN
SEC Filings
SEC Filings
- 1/29/26 - Form 8-K
- 1/26/26 - Form 8-K
- 1/22/26 - Form 4
- BMRN's page on the SEC website
- More